Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. PRKAG2 - Wikipedia
PRKAG2 - Wikipedia
From Wikipedia, the free encyclopedia

Protein-coding gene in the species Homo sapiens
PRKAG2
Identifiers
AliasesPRKAG2, AAKG, AAKG2, CMH6, H91620p, WPWS, protein kinase AMP-activated non-catalytic subunit gamma 2
External IDsOMIM: 602743; MGI: 1336153; HomoloGene: 136125; GeneCards: PRKAG2; OMA:PRKAG2 - orthologs
Gene location (Human)
Chromosome 7 (human)
Chr.Chromosome 7 (human)[1]
Chromosome 7 (human)
Genomic location for PRKAG2
Genomic location for PRKAG2
Band7q36.1Start151,556,124 bp[1]
End151,877,125 bp[1]
Gene location (Mouse)
Chromosome 5 (mouse)
Chr.Chromosome 5 (mouse)[2]
Chromosome 5 (mouse)
Genomic location for PRKAG2
Genomic location for PRKAG2
Band5|5 A3Start25,067,742 bp[2]
End25,305,640 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • right auricle of heart

  • cardiac muscle tissue of right atrium

  • right coronary artery

  • left ventricle

  • left coronary artery

  • popliteal artery

  • tibial arteries

  • gastric mucosa

  • nucleus accumbens

  • apex of heart
Top expressed in
  • seminiferous tubule

  • atrium

  • spermatid

  • dentate gyrus of hippocampal formation granule cell

  • tail of embryo

  • superior frontal gyrus

  • primary visual cortex

  • atrioventricular valve

  • spermatocyte

  • subiculum
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
  • nucleotide binding
  • ADP binding
  • AMP-activated protein kinase activity
  • protein kinase activator activity
  • phosphorylase kinase regulator activity
  • AMP binding
  • cAMP-dependent protein kinase regulator activity
  • cAMP-dependent protein kinase inhibitor activity
  • ATP binding
  • protein kinase binding
  • adenyl ribonucleotide binding
Cellular component
  • cytosol
  • nucleoplasm
  • nucleotide-activated protein kinase complex
  • extracellular space
Biological process
  • carnitine shuttle
  • intracellular signal transduction
  • sterol biosynthetic process
  • regulation of fatty acid oxidation
  • negative regulation of protein kinase activity
  • regulation of glucose import
  • lipid metabolism
  • regulation of fatty acid biosynthetic process
  • fatty acid metabolic process
  • regulation of glycolytic process
  • protein phosphorylation
  • fatty acid biosynthetic process
  • positive regulation of peptidyl-threonine phosphorylation
  • regulation of fatty acid metabolic process
  • ATP biosynthetic process
  • glycogen metabolic process
  • regulation of catalytic activity
  • macroautophagy
  • positive regulation of protein kinase activity
  • regulation of signal transduction by p53 class mediator
  • activation of protein kinase activity
  • negative regulation of protein serine/threonine kinase activity
  • regulation of macroautophagy
  • regulation of protein serine/threonine kinase activity
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

51422

108099

Ensembl

ENSG00000106617

ENSMUSG00000028944

UniProt

Q9UGJ0

Q91WG5

RefSeq (mRNA)
NM_001040633
NM_001304527
NM_001304531
NM_016203
NM_024429

NM_001363698

NM_001170555
NM_001170556
NM_145401
NM_001310480

RefSeq (protein)
NP_001035723
NP_001291456
NP_001291460
NP_057287
NP_077747

NP_001350627

NP_001164026
NP_001164027
NP_001297409
NP_663376

Location (UCSC)Chr 7: 151.56 – 151.88 MbChr 5: 25.07 – 25.31 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

5'-AMP-activated protein kinase subunit gamma-2 is an enzyme that in humans is encoded by the PRKAG2 gene.[5][6][7]

Function

[edit]

AMP-activated protein kinase (AMPK) is a heterotrimeric protein composed of a catalytic alpha subunit, a noncatalytic beta subunit, and a noncatalytic regulatory gamma subunit. Various forms of each of these subunits exist, encoded by different genes. AMPK is an important energy-sensing enzyme that monitors cellular energy status and functions by inactivating key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. This gene is a member of the AMPK gamma subunit family and encodes a protein with four CBS domains. Mutations in this gene have been associated with ventricular pre-excitation (Wolff–Parkinson–White syndrome), progressive conduction system disease and cardiac hypertrophy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.[7]

Interactions

[edit]

PRKAG2 has been shown to interact with PRKAB2[8] and PRKAB1.[8]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000106617 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028944 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, et al. (January 1996). "Mammalian AMP-activated protein kinase subfamily". The Journal of Biological Chemistry. 271 (2): 611–614. doi:10.1074/jbc.271.2.611. PMID 8557660.
  6. ^ Gao G, Fernandez CS, Stapleton D, Auster AS, Widmer J, Dyck JR, et al. (April 1996). "Non-catalytic beta- and gamma-subunit isoforms of the 5'-AMP-activated protein kinase". The Journal of Biological Chemistry. 271 (15): 8675–8681. doi:10.1074/jbc.271.15.8675. PMID 8621499.
  7. ^ a b "Entrez Gene: PRKAG2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit".
  8. ^ a b Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D (March 2000). "Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding". The Biochemical Journal. 346 Pt 3 (Pt 3): 659–669. doi:10.1042/0264-6021:3460659. PMC 1220898. PMID 10698692.

Further reading

[edit]
  • Gollob MH, Green MS, Tang AS, Roberts R (May 2002). "PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy". Current Opinion in Cardiology. 17 (3): 229–234. doi:10.1097/00001573-200205000-00004. PMID 12015471. S2CID 33599152.
  • Gollob MH (February 2003). "Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome". Biochemical Society Transactions. 31 (Pt 1): 228–231. doi:10.1042/BST0310228. PMID 12546691.
  • Ofir M, Hochhauser E, Vidne BA, Freimark D, Arad M (October 2007). "[AMP-activated protein kinase: how a mistake in energy gauge causes glycogen storage]". Harefuah. 146 (10): 770–5, 813–4. PMID 17990392.
  • Hofmann B, Nishanian P, Baldwin RL, Insixiengmay P, Nel A, Fahey JL (December 1990). "HIV inhibits the early steps of lymphocyte activation, including initiation of inositol phospholipid metabolism". Journal of Immunology. 145 (11): 3699–3705. doi:10.4049/jimmunol.145.11.3699. PMID 1978848.
  • MacRae CA, Ghaisas N, Kass S, Donnelly S, Basson CT, Watkins HC, et al. (September 1995). "Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3". The Journal of Clinical Investigation. 96 (3): 1216–1220. doi:10.1172/JCI118154. PMC 185741. PMID 7657794.
  • Hofmann B, Nishanian P, Nguyen T, Insixiengmay P, Fahey JL (July 1993). "Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 90 (14): 6676–6680. Bibcode:1993PNAS...90.6676H. doi:10.1073/pnas.90.14.6676. PMC 46995. PMID 7688126.
  • Hofmann B, Nishanian P, Fan J, Nguyen T, Fahey JL (July 1994). "HIV Gag p17 protein impairs proliferation of normal lymphocytes in vitro". AIDS. 8 (7): 1016–1017. doi:10.1097/00002030-199407000-00025. PMID 7946090.
  • Swingler S, Gallay P, Camaur D, Song J, Abo A, Trono D (June 1997). "The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix". Journal of Virology. 71 (6): 4372–4377. doi:10.1128/JVI.71.6.4372-4377.1997. PMC 191654. PMID 9151826.
  • Stapleton D, Woollatt E, Mitchelhill KI, Nicholl JK, Fernandez CS, Michell BJ, et al. (June 1997). "AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location". FEBS Letters. 409 (3): 452–456. Bibcode:1997FEBSL.409..452S. doi:10.1016/S0014-5793(97)00569-3. PMID 9224708. S2CID 39329574.
  • Chen P, Mayne M, Power C, Nath A (September 1997). "The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases". The Journal of Biological Chemistry. 272 (36): 22385–22388. doi:10.1074/jbc.272.36.22385. PMID 9278385.
  • Zidovetzki R, Wang JL, Chen P, Jeyaseelan R, Hofman F (July 1998). "Human immunodeficiency virus Tat protein induces interleukin 6 mRNA expression in human brain endothelial cells via protein kinase C- and cAMP-dependent protein kinase pathways". AIDS Research and Human Retroviruses. 14 (10): 825–833. doi:10.1089/aid.1998.14.825. PMID 9671211.
  • Mayne M, Bratanich AC, Chen P, Rana F, Nath A, Power C (1998). "HIV-1 tat molecular diversity and induction of TNF-alpha: implications for HIV-induced neurological disease". Neuroimmunomodulation. 5 (3–4): 184–192. doi:10.1159/000026336. PMID 9730685. S2CID 19529677.
  • Sanger Centre T, Washington University Genome Sequencing Cente T (November 1998). "Toward a complete human genome sequence". Genome Research. 8 (11): 1097–1108. doi:10.1101/gr.8.11.1097. PMID 9847074.
  • Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D (March 2000). "Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding". The Biochemical Journal. 346 Pt 3 (Pt 3): 659–669. doi:10.1042/0264-6021:3460659. PMC 1220898. PMID 10698692.
  • Lang T, Yu L, Tu Q, Jiang J, Chen Z, Xin Y, et al. (December 2000). "Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant gamma2 subunit of 5'-AMP-activated protein kinase, to human chromosome 7q36". Genomics. 70 (2): 258–263. doi:10.1006/geno.2000.6376. PMID 11112354.
  • Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, et al. (May 2001). "Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis". Human Molecular Genetics. 10 (11): 1215–1220. doi:10.1093/hmg/10.11.1215. PMID 11371514.
  • Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, et al. (June 2001). "Identification of a gene responsible for familial Wolff-Parkinson-White syndrome". The New England Journal of Medicine. 344 (24): 1823–1831. doi:10.1056/NEJM200106143442403. PMID 11407343.
  • Hamilton SR, Stapleton D, O'Donnell JB, Kung JT, Dalal SR, Kemp BE, et al. (July 2001). "An activating mutation in the gamma1 subunit of the AMP-activated protein kinase". FEBS Letters. 500 (3): 163–168. Bibcode:2001FEBSL.500..163H. doi:10.1016/S0014-5793(01)02602-3. PMID 11445078. S2CID 85248755.

External links

[edit]
  • GeneReviews/NCBI/NIH/UW entry on Familial Hypertrophic Cardiomyopathy Overview
  • v
  • t
  • e
Kinases: Serine/threonine-specific protein kinases (EC 2.7.11-12)
Serine/threonine-specific protein kinases (EC 2.7.11.1-EC 2.7.11.20)
Non-specific serine/threonine protein kinases (EC 2.7.11.1)
  • LATS1
  • LATS2
  • MAST1
  • MAST2
  • STK38
  • STK38L
  • CIT
  • ROCK1
  • SGK
  • SGK2
  • SGK3
  • Protein kinase B
    • AKT1
    • AKT2
    • AKT3
  • Ataxia telangiectasia mutated
  • mTOR
  • EIF-2 kinases
    • PKR
    • HRI
    • EIF2AK3
    • EIF2AK4
  • Wee1
    • WEE1
Pyruvate dehydrogenase kinase (EC 2.7.11.2)
  • PDK1
  • PDK2
  • PDK3
  • PDK4
Dephospho-(reductase kinase) kinase (EC 2.7.11.3)
  • AMP-activated protein kinase α
    • PRKAA1
    • PRKAA2
  • β
    • PRKAB1
    • PRKAB2
  • γ
    • PRKAG1
    • PRKAG2
    • PRKAG3
3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring) kinase (EC 2.7.11.4)
  • BCKDK
  • BCKDHA
  • BCKDHB
(isocitrate dehydrogenase (NADP+)) kinase (EC 2.7.11.5)
  • IDH2
  • IDH3A
  • IDH3B
  • IDH3G
(tyrosine 3-monooxygenase) kinase (EC 2.7.11.6)
  • STK4
Myosin-heavy-chain kinase (EC 2.7.11.7)
  • Aurora kinase
    • Aurora A kinase
    • Aurora B kinase
    • Aurora C kinase
Fas-activated serine/threonine kinase (EC 2.7.11.8)
  • FASTK
  • STK10
Goodpasture-antigen-binding protein kinase (EC 2.7.11.9)
  • -
IκB kinase (EC 2.7.11.10)
  • CHUK
  • IKK2
  • TBK1
  • IKBKE
  • IKBKG
  • IKBKAP
cAMP-dependent protein kinase (EC 2.7.11.11)
  • Protein kinase A
  • PRKACG
  • PRKACB
  • PRKACA
  • PRKY
cGMP-dependent protein kinase (EC 2.7.11.12)
  • Protein kinase G
  • PRKG1
Protein kinase C (EC 2.7.11.13)
  • Protein kinase C
  • Protein kinase Cζ
  • PKC alpha
  • PRKCB1
  • PRKCD
  • PRKCE
  • PRKCH
  • PRKCG
  • PRKCI
  • PRKCQ
  • Protein kinase N1
  • PKN2
  • PKN3
Rhodopsin kinase (EC 2.7.11.14)
  • Rhodopsin kinase
Beta adrenergic receptor kinase (EC 2.7.11.15)
  • Beta adrenergic receptor kinase
  • Beta adrenergic receptor kinase-2
G-protein coupled receptor kinases (EC 2.7.11.16)
  • GRK4
  • GRK5
  • GRK6
Ca2+/calmodulin-dependent (EC 2.7.11.17)
  • BRSK2
  • CAMK1
  • CAMK1A
  • CAMK1B
  • CAMK1D
  • CAMK1G
  • CAMK2
  • CAMK2A
  • CAMK2B
  • CAMK2D
  • CAMK2G
  • CAMK4
  • MLCK
  • CASK
  • CHEK1
  • CHEK2
  • DAPK1
  • DAPK2
  • DAPK3
  • STK11
  • MAPKAPK2
  • MAPKAPK3
  • MAPKAPK5
  • MARK1
  • MARK2
  • MARK3
  • MARK4
  • MELK
  • MKNK1
  • MKNK2
  • NUAK1
  • NUAK2
  • OBSCN
  • PASK
  • PHKG1
  • PHKG2
  • PIM1
  • PIM2
  • PKD1
  • PRKD2
  • PRKD3
  • PSKH1
  • SNF1LK2
  • KIAA0999
  • STK40
  • SNF1LK
  • SNRK
  • SPEG
  • TSSK2
  • Kalirin
  • TRIB1
  • TRIB2
  • TRIB3
  • TRIO
  • Titin
  • DCLK1
Myosin light-chain kinase (EC 2.7.11.18)
  • MYLK
  • MYLK2
  • MYLK3
  • MYLK4
Phosphorylase kinase (EC 2.7.11.19)
  • PHKA1
  • PHKA2
  • PHKB
  • PHKG1
  • PHKG2
Elongation factor 2 kinase (EC 2.7.11.20)
  • EEF2K
  • STK19
Polo kinase (EC 2.7.11.21)
  • PLK1
  • PLK2
  • PLK3
  • PLK4
Serine/threonine-specific protein kinases (EC 2.7.11.21-EC 2.7.11.30)
Polo kinase (EC 2.7.11.21)
  • PLK1
  • PLK2
  • PLK3
  • PLK4
Cyclin-dependent kinase (EC 2.7.11.22)
  • CDK1
  • CDK2
  • CDKL2
  • CDK3
  • CDK4
  • CDK5
  • CDKL5
  • CDK6
  • CDK7
  • CDK8
  • CDK9
  • CDK10
  • CDK12
  • CDC2L5
  • PCTK1
  • PCTK2
  • PCTK3
  • PFTK1
  • CDC2L1
(RNA-polymerase)-subunit kinase (EC 2.7.11.23)
  • RPS6KA5
  • RPS6KA4
  • P70S6 kinase
  • P70-S6 Kinase 1
  • RPS6KB2
  • RPS6KA2
  • RPS6KA3
  • RPS6KA1
  • RPS6KC1
Mitogen-activated protein kinase (EC 2.7.11.24)
  • Extracellular signal-regulated
    • MAPK1
    • MAPK3
    • MAPK4
    • MAPK6
    • MAPK7
    • MAPK12
    • MAPK15
  • C-Jun N-terminal
    • MAPK8
    • MAPK9
    • MAPK10
  • P38 mitogen-activated protein
    • MAPK11
    • MAPK13
    • MAPK14
MAP3K (EC 2.7.11.25)
  • MAP kinase kinase kinases
    • MAP3K1
    • MAP3K2
    • MAP3K3
    • MAP3K4
    • MAP3K5
    • MAP3K6
    • MAP3K7
    • MAP3K8
  • RAFs
    • ARAF
    • BRAF
    • KSR1
    • KSR2
  • MLKs
    • MAP3K12
    • MAP3K13
    • MAP3K9
    • MAP3K10
    • MAP3K11
    • MAP3K7
    • ZAK
  • CDC7
  • MAP3K14
Tau-protein kinase (EC 2.7.11.26)
  • TPK1
  • TTK
  • GSK-3
(acetyl-CoA carboxylase) kinase (EC 2.7.11.27)
  • -
Tropomyosin kinase (EC 2.7.11.28)
  • -
Low-density-lipoprotein receptor kinase (EC 2.7.11.29)
  • -
Receptor protein serine/threonine kinase (EC 2.7.11.30)
  • Bone morphogenetic protein receptors
    • BMPR1
    • BMPR1A
    • BMPR1B
    • BMPR2
  • ACVR1
  • ACVR1B
  • ACVR1C
  • ACVR2A
  • ACVR2B
  • ACVRL1
  • Anti-Müllerian hormone receptor
Dual-specificity kinases (EC 2.7.12)
MAP2K
  • MAP2K1
  • MAP2K2
  • MAP2K3
  • MAP2K4
  • MAP2K5
  • MAP2K6
  • MAP2K7
  • v
  • t
  • e
Enzymes
Activity
  • Active site
  • Binding site
  • Catalytic triad
  • Oxyanion hole
  • Enzyme promiscuity
  • Diffusion-limited enzyme
  • Cofactor
  • Enzyme catalysis
Regulation
  • Allosteric regulation
  • Cooperativity
  • Enzyme inhibitor
  • Enzyme activator
Classification
  • EC number
  • Enzyme superfamily
  • Enzyme family
  • List of enzymes
Kinetics
  • Enzyme kinetics
  • Eadie–Hofstee diagram
  • Hanes–Woolf plot
  • Lineweaver–Burk plot
  • Michaelis–Menten kinetics
Types
  • EC1 Oxidoreductases (list)
  • EC2 Transferases (list)
  • EC3 Hydrolases (list)
  • EC4 Lyases (list)
  • EC5 Isomerases (list)
  • EC6 Ligases (list)
  • EC7 Translocases (list)
Portal:
  • icon Biology
Stub icon

This article on a gene on human chromosome 7 is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=PRKAG2&oldid=1300695684"
Categories:
  • Genes on human chromosome 7
  • EC 2.7.11
  • Human chromosome 7 gene stubs
Hidden categories:
  • CS1: long volume value
  • Articles with short description
  • Short description matches Wikidata
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id